Understanding Bladder Cancer Basics

Bladder cancer starts in the cells that line the inside of the bladder, a hollow organ in the lower abdomen that stores urine. According to the American Cancer Society, an estimated 82,290 new cases of bladder cancer were diagnosed in the United States in 2023, making it the fourth most common cancer in men and the ninth in women. Understanding what bladder cancer is helps you have informed conversations with your medical team about treatment options.

Understanding Parkinson's Disease and Age of Diagnosis →

There are three main types of bladder cancer, classified by the type of cells where cancer develops. Urothelial carcinoma (also called transitional cell carcinoma) is the most common type, accounting for about 90% of cases. Squamous cell carcinoma and adenocarcinoma are less common but may require different treatment approaches. The stage of cancer—how far it has spread—significantly influences which treatments your doctors might discuss with you.

Bladder cancer is also classified by how deep it has invaded the bladder wall. Non-muscle-invasive bladder cancer affects the inner lining and muscle layer but has not reached the muscle that allows the bladder to contract. Muscle-invasive bladder cancer has spread into or through the muscle layer of the bladder wall. This distinction matters because treatment options differ considerably between these categories.

Symptoms may include blood in urine (hematuria), pain during urination, urinary frequency, and urinary urgency. However, these symptoms can also result from other conditions. A diagnosis typically involves imaging tests like CT scans or ultrasounds, followed by a cystoscopy—a procedure where a doctor inserts a thin tube with a camera into the bladder to visualize abnormal tissue. If cancer is suspected, a biopsy (tissue sample) confirms the diagnosis and determines the cancer type and stage.

Practical Takeaway: Learning the type and stage of your bladder cancer provides the foundation for understanding treatment recommendations. Request your pathology report and staging information from your medical team, and write down any questions about what these results mean for your specific situation.

Non-Muscle-Invasive Bladder Cancer Treatments

Non-muscle-invasive bladder cancer represents approximately 70-75% of new bladder cancer diagnoses. Because this cancer has not invaded the muscle layer, treatment often focuses on removing visible tumors and preventing recurrence. The primary treatment for early-stage non-muscle-invasive cancer is transurethral resection of the bladder tumor (TURBT), a procedure performed through the urethra without external incisions.

Learn Typing Speed and Accuracy Tips →

During TURBT, a urologist inserts a resectoscope (an instrument with a wire loop or laser) through the urethra to remove tumors and surrounding tissue. This procedure serves both diagnostic and therapeutic purposes—it removes cancer and provides tissue samples for staging. TURBT can be performed in an outpatient setting or with a brief hospital stay. Recovery typically takes one to two weeks, during which patients may experience mild bleeding or discomfort during urination. According to the National Cancer Institute, TURBT is successful in treating approximately 70% of non-muscle-invasive cases without recurrence.

After TURBT, many patients receive intravesical therapy—medication delivered directly into the bladder through a catheter. Two main types of intravesical therapy are used:

  • Bacillus Calmette-Guérin (BCG): This is a live weakened bacterium that stimulates the immune system to attack cancer cells. BCG is considered more effective than chemotherapy for preventing recurrence in intermediate and high-risk non-muscle-invasive cancers. Treatment involves weekly instillations for six weeks, often followed by maintenance therapy over one to three years.
  • Intravesical chemotherapy: Drugs like mitomycin C are delivered directly into the bladder, where they kill cancer cells with minimal systemic side effects. This approach is often recommended for low-risk cancers or as an alternative when BCG is not suitable.

Regular follow-up monitoring is essential for non-muscle-invasive bladder cancer because recurrence rates range from 50-70%. Surveillance typically includes cystoscopy every three months for the first two years, then at longer intervals if no recurrence is detected. Some patients may eventually require more aggressive treatment if their cancer recurs or progresses to muscle-invasive disease.

Practical Takeaway: If you have non-muscle-invasive bladder cancer, ask your doctor about the specific risk category (low, intermediate, or high) and what follow-up schedule they recommend. Understanding your surveillance plan helps you stay organized with appointments and know what to expect long-term.

Muscle-Invasive Bladder Cancer Surgery Options

Muscle-invasive bladder cancer requires more aggressive treatment because the cancer has penetrated the muscle layer of the bladder wall. Radical cystoprostatectomy (in men) or radical cystectomy (in women) has been the gold standard treatment for decades. This surgery removes the entire bladder, surrounding tissues, and nearby lymph nodes. In men, the procedure also removes the prostate and seminal vesicles; in women, it removes the uterus, ovaries, and part of the vaginal wall to ensure complete cancer removal.

Learn Chess Basics for Complete Beginners Today →

Radical cystectomy is a major surgical procedure typically lasting two to four hours, performed under general anesthesia. Patients usually spend three to seven days in the hospital and require four to six weeks for initial recovery. According to the American College of Surgeons, this surgery successfully removes all cancer in the bladder in approximately 80-90% of cases when there is no evidence of cancer spread beyond the bladder.

A critical component of cystectomy is urinary diversion—creating a new way for urine to leave the body since the bladder is removed. Three main diversion options exist:

  • Ileal conduit (urostomy): A surgeon creates a pouch using a segment of small intestine, with one end brought to the abdominal surface as an opening called a stoma. Urine continuously drains into an external pouch worn on the skin. This is the most common diversion method and typically requires the least surgical time.
  • Continent pouch (Indiana pouch or Koch pouch): The surgeon creates an internal reservoir from bowel tissue that stores urine. Patients empty the pouch several times daily by inserting a catheter through a valve opening in the abdomen. This option allows greater control but requires more complex surgery and patient management.
  • Neobladder (orthotopic diversion): Surgeons construct a new bladder from bowel tissue and attach it to the urethra, allowing more natural urination. Patients may retain some urinary control, though nighttime incontinence is common. This approach requires excellent surgical technique and patient selection, as it is most suitable for younger, healthier patients without kidney or liver disease.

Chemotherapy before surgery (neoadjuvant therapy) has shown improved survival rates in muscle-invasive bladder cancer. Studies demonstrate that cisplatin-based chemotherapy given before cystectomy increases five-year survival rates by approximately 5-10% compared to surgery alone. Your medical team will discuss whether you are a candidate for preoperative chemotherapy based on your overall health and kidney function.

Practical Takeaway: If muscle-invasive bladder cancer surgery is recommended, schedule consultations with your surgical team to discuss urinary diversion options in detail. Ask about each option's impact on daily life, and consider connecting with patient support groups to hear from others who have chosen different diversion methods.

Radiation and Chemotherapy Treatments

Radiation therapy and chemotherapy represent important treatment options, particularly when surgery is not feasible or as complementary therapy with surgery. These systemic and localized treatments work differently and may be used in various combinations depending on cancer stage, patient health status, and treatment goals.

Your Free Guide to Managing Android Passwords →

External beam radiation therapy (EBRT) directs high-energy beams at the bladder and surrounding tissues to destroy cancer cells. Modern radiation techniques like intensity-modulated radiation therapy (IMRT) allow doctors to shape radiation beams to match the tumor's contour, minimizing damage to healthy tissue. A typical course involves five treatments per week over five to seven weeks. For muscle-invasive bladder cancer